{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:27:00Z","timestamp":1781234820937,"version":"3.54.1"},"reference-count":58,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Adolescent and Young Adult Oncology"],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Soft tissue sarcomas (STS) account for 8% of all cancers in adolescents and young adults (AYAs). Metastatic STS contribute significantly to disease-related mortality in this age group; however, data are limited due to under-representation in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>AYAs aged 18\u201339 years, diagnosed with metastatic STS between 1990 and 2012, were identified from The Royal Marsden Hospital database. Outcomes of interest were clinical characteristics, treatment patterns, overall survival (OS), and prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Overall, 455 patients were included. Median age at diagnosis of metastatic STS was 33 years (interquartile range [IQR] 27\u201337 years). The most common histological subtypes were leiomyosarcoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200968, 15%), synovial sarcoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200968, 15%), Ewing sarcoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944, 10%), and rhabdomyosarcoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200935, 8%). Treatments included systemic therapy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009395, 87%; median 2 lines [IQR 1\u20133]; clinical trial\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200993, 22%), radiotherapy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009297, 66%), and metastasectomy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009191, 43%). Median duration between last chemotherapy regimen and death was 4.6 months (IQR 2\u201310). Median OS was 19.2 months (95% confidence interval [CI] 15.8\u201322.2); 5-year OS was 16%. Of common subtypes, patients with rhabdomyosarcoma had the worst OS (8.8 months; 95% CI 7.9\u201311.4). Adverse prognostic factors included male gender, synchronous metastases, bone or liver metastases, first-line polychemotherapy, and no metastasectomy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Outcomes were variable; patients with supposed chemosensitive subtypes had particularly poor survival. The diverse behavior of STS in AYAs highlights the need for subtype-specific clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jayao.2020.0010","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T16:23:21Z","timestamp":1588868601000},"page":"628-638","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience"],"prefix":"10.1177","volume":"9","author":[{"given":"Eugenie","family":"Younger","sequence":"first","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Husson","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."},{"name":"Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Asare","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Benson","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Judson","sequence":"additional","affiliation":[{"name":"Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Miah","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."},{"name":"Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Al-Muderis","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."},{"name":"Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom."},{"name":"Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-2-14"},{"key":"e_1_3_7_3_2","first-page":"147","article-title":"Epidemiology and therapies for metastatic sarcoma","volume":"5","author":"Amankwah EK","year":"2013","unstructured":"Amankwah EK, , Conley AP, , Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol. 2013; 5:147\u201362.","journal-title":"Clin Epidemiol"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00162-5"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2005.03.007"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30099-2"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25840"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000161762.53175.e4"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.705891"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24695"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.03.006"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20995"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2018.0136"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.007"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.001"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32367"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0868-7"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25538"},{"key":"e_1_3_7_19_2","first-page":"4485","article-title":"The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients","volume":"32","author":"Van Gaal JC","year":"2012","unstructured":"Van Gaal JC, , Van Der Graaf WTA, , Rikhof B, et al. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Res. 2012; 32:4485\u201398.","journal-title":"A multicenter study. Anticancer Res"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.7483"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25833"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-1-65"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S178979"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26096"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.10.014"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.11.013"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq338"},{"key":"e_1_3_7_28_2","article-title":"Therapeutic targets for malignant peripheral nerve sheath tumors","volume":"14","author":"Wu LMN","year":"2019","unstructured":"Wu LMN, , Lu QR. Therapeutic targets for malignant peripheral nerve sheath tumors. Future Neurol. 2019; 14. DOI:10.2217\/fnl-2018-0026.","journal-title":"Future Neurol"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/348910"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000486419"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp485"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0831-7"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24370"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24424"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.375"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0147"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu362"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70175-4"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2918-1"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.11.003"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds659"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.01.006"},{"key":"e_1_3_7_44_2","unstructured":"National Institute of Clinical Excellence (NICE). Trabectedin for the treatment of advanced soft tissue sarcoma. Technology appraisal guidance [TA185] Published date: February 24 2010. Updated February 2014. Accessed March30 2020 from: https:\/\/www.nice.org.uk\/Guidance\/ta185"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.150"},{"key":"e_1_3_7_46_2","first-page":"72","article-title":"Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas","volume":"46","author":"Sleijfer S","year":"2010","unstructured":"Sleijfer S, , Ouali M, , van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010; 46:72\u201383.","journal-title":"An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3683-8"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30757"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156686"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30215-3"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.09.008"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1953"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32035"},{"key":"e_1_3_7_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-015-0026-y"},{"key":"e_1_3_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.023"},{"key":"e_1_3_7_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0465"},{"key":"e_1_3_7_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30147-4"},{"key":"e_1_3_7_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.028"}],"container-title":["Journal of Adolescent and Young Adult Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jayao.2020.0010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jayao.2020.0010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jayao.2020.0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:49:23Z","timestamp":1777492163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jayao.2020.0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.1089\/jayao.2020.0010"],"URL":"https:\/\/doi.org\/10.1089\/jayao.2020.0010","relation":{},"ISSN":["2156-5333","2156-535X"],"issn-type":[{"value":"2156-5333","type":"print"},{"value":"2156-535X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}